BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 20950259)

  • 1. Emerging therapeutic targets and agents for glioblastoma migrating cells.
    Di C; Mattox AK; Harward S; Adamson C
    Anticancer Agents Med Chem; 2010 Sep; 10(7):543-55. PubMed ID: 20950259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. STAT3 as a Therapeutic Target for Glioblastoma.
    Liu Y; Li C; Lin J
    Anticancer Agents Med Chem; 2010 Sep; 10(7):512-9. PubMed ID: 20879983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteins of the Wnt signaling pathway as targets for the regulation of CD133+ cancer stem cells in glioblastoma.
    Shevchenko V; Arnotskaya N; Korneyko M; Zaytsev S; Khotimchenko Y; Sharma H; Bryukhovetskiy I
    Oncol Rep; 2019 May; 41(5):3080-3088. PubMed ID: 30864699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The PI3K inhibitor GDC-0941 enhances radiosensitization and reduces chemoresistance to temozolomide in GBM cell lines.
    Shi F; Guo H; Zhang R; Liu H; Wu L; Wu Q; Liu J; Liu T; Zhang Q
    Neuroscience; 2017 Mar; 346():298-308. PubMed ID: 28147244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting glioblastoma cancer stem cells: the next great hope?
    Khan IS; Ehtesham M
    Neurosurg Focus; 2014 Dec; 37(6):E7. PubMed ID: 25581936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proneural-mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?
    Nakano I
    Future Oncol; 2014; 10(9):1527-30. PubMed ID: 25145421
    [No Abstract]   [Full Text] [Related]  

  • 9. Glucocorticoids promote a glioma stem cell-like phenotype and resistance to chemotherapy in human glioblastoma primary cells: Biological and prognostic significance.
    Kostopoulou ON; Mohammad AA; Bartek J; Winter J; Jung M; Stragliotto G; Söderberg-Nauclér C; Landázuri N
    Int J Cancer; 2018 Mar; 142(6):1266-1276. PubMed ID: 29067692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review.
    Anjum K; Shagufta BI; Abbas SQ; Patel S; Khan I; Shah SAA; Akhter N; Hassan SSU
    Biomed Pharmacother; 2017 Aug; 92():681-689. PubMed ID: 28582760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
    Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
    Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. G-protein-coupled receptors as therapeutic targets for glioblastoma.
    Byrne KF; Pal A; Curtin JF; Stephens JC; Kinsella GK
    Drug Discov Today; 2021 Dec; 26(12):2858-2870. PubMed ID: 34271165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self‑renewal signaling pathways and differentiation therapies of glioblastoma stem cells (Review).
    Jin J; Grigore F; Chen CC; Li M
    Int J Oncol; 2021 Jul; 59(1):. PubMed ID: 34013362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Investigational Perspective for Purines Against Glioblastoma Invasiveness.
    Giuliani P; Zuccarini M; Carluccio M; Ziberi S; Di Iorio P; Caciagli F; Ciccarelli R
    Curr Drug Targets; 2018; 19(16):1871-1881. PubMed ID: 29484991
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoresistance caused by the microenvironment of glioblastoma and the corresponding solutions.
    Zhang X; Ding K; Wang J; Li X; Zhao P
    Biomed Pharmacother; 2019 Jan; 109():39-46. PubMed ID: 30391707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular pathways and potential therapeutic targets in glioblastoma multiforme.
    Wardak Z; Choe KS
    Expert Rev Anticancer Ther; 2013 Nov; 13(11):1307-18. PubMed ID: 24168050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Development and Angiogenesis in Adult Brain Tumor: Glioblastoma.
    Ahir BK; Engelhard HH; Lakka SS
    Mol Neurobiol; 2020 May; 57(5):2461-2478. PubMed ID: 32152825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hitting a Moving Target: Glioma Stem Cells Demand New Approaches in Glioblastoma Therapy.
    Spencer DA; Auffinger BM; Murphy JP; Muroski ME; Qiao J; Gorind Y; Lesniak MS
    Curr Cancer Drug Targets; 2017; 17(3):236-254. PubMed ID: 27993114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Arsenic trioxide disrupts glioma stem cells via promoting PML degradation to inhibit tumor growth.
    Zhou W; Cheng L; Shi Y; Ke SQ; Huang Z; Fang X; Chu CW; Xie Q; Bian XW; Rich JN; Bao S
    Oncotarget; 2015 Nov; 6(35):37300-15. PubMed ID: 26510911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in histone deacetylase inhibitors in targeting glioblastoma stem cells.
    Reddy RG; Bhat UA; Chakravarty S; Kumar A
    Cancer Chemother Pharmacol; 2020 Aug; 86(2):165-179. PubMed ID: 32638092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.